Vertex saw disappointments in 2022, that may be about to change. Profitability may improve as onerous hedging rolled off for Q4. Shares could double from here to around $18 on my estimates (range: $10 ...

The US Food and Drug Administration (FDA) has accepted Vertex Pharmaceuticals’ completed new drug application (NDA) submission for suzetrigine, as the company’s non-opioid-based treatment for acute ...

On Monday, Goldman Sachs reaffirmed a Buy rating on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (NASDAQ:VRTX), with a set price target of $598.00. At a recent event, Vertex presented ...

HOUSTON, TX / ACCESSWIRE / June 6, 2022 / Vertex Energy, Inc. (NASDAQ:VTNR) ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, today announced it ...

Now, it’s worth noting Stock Advisor’s total average return is 984 % — a market-crushing outperformance compared to 195% for the S&P 500. Don't miss the latest top 10 list, available with Stock ...